Germany: approval for first clinical trial of COVID-19 vaccine candidates

By: Nina Hoppmann
Created: 22 April 2020 - 12:04
Updated: 22 April 2020 - 12:04

In a press release, German biotech BioNTech SE and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program. 

The company has designed four vaccine candidates that deliver the genetic code for four different COVID-19 antigens. The dose escalation portion of the Phase I/II trial will include approximately 200 healthy subjects between the ages of 18 to 55 to determine the optimal dose for further studies, as well as evaluating safety and immunogenicity. The study will also evaluate the effects of repeated immunization for three of the four vaccine candidates.

Find the press relesase here: https://investors.biontech.de/news-releases/news-release-details/biontech-and-pfizer-announce-regulatory-approval-german 

Do you know of any other progresses in other countries?